335 related articles for article (PubMed ID: 37143664)
1. Vγ9Vδ2 T-cell immunotherapy in blood cancers: ready for prime time?
Giannotta C; Autino F; Massaia M
Front Immunol; 2023; 14():1167443. PubMed ID: 37143664
[TBL] [Abstract][Full Text] [Related]
2. Target tumor microenvironment by innate T cells.
Li YR; Wilson M; Yang L
Front Immunol; 2022; 13():999549. PubMed ID: 36275727
[TBL] [Abstract][Full Text] [Related]
3. γδ T Cells in Tumor Microenvironment.
Imbert C; Olive D
Adv Exp Med Biol; 2020; 1273():91-104. PubMed ID: 33119877
[TBL] [Abstract][Full Text] [Related]
4. The way of interaction between Vγ9Vδ2 T cells and tumor cells.
Zhang T; Wang J; Zhao A; Xia L; Jin H; Xia S; Shi T
Cytokine; 2023 Feb; 162():156108. PubMed ID: 36527892
[TBL] [Abstract][Full Text] [Related]
5. Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future.
Saura-Esteller J; de Jong M; King LA; Ensing E; Winograd B; de Gruijl TD; Parren PWHI; van der Vliet HJ
Front Immunol; 2022; 13():915837. PubMed ID: 35784326
[TBL] [Abstract][Full Text] [Related]
6. Solid Tumor Microenvironment Can Harbor and Support Functional Properties of Memory T Cells.
Sullivan PM; Reed SJ; Kalia V; Sarkar S
Front Immunol; 2021; 12():706150. PubMed ID: 34867942
[TBL] [Abstract][Full Text] [Related]
7. Renal Cell Carcinoma-Infiltrating CD3
Lee HW; Park C; Joung JG; Kang M; Chung YS; Oh WJ; Yeom SY; Park WY; Kim TJ; Seo SI
Curr Issues Mol Biol; 2021 May; 43(1):226-239. PubMed ID: 34071865
[TBL] [Abstract][Full Text] [Related]
8. Harnessing Unconventional T Cells and Innate Lymphoid Cells to Prevent and Treat Hematological Malignancies: Prospects for New Immunotherapy.
Allegra A; Casciaro M; Lo Presti E; Musolino C; Gangemi S
Biomolecules; 2022 May; 12(6):. PubMed ID: 35740879
[TBL] [Abstract][Full Text] [Related]
9. Unconventional T cells and kidney disease.
Kaminski H; Couzi L; Eberl M
Nat Rev Nephrol; 2021 Dec; 17(12):795-813. PubMed ID: 34446934
[TBL] [Abstract][Full Text] [Related]
10. Antigen-Presenting Cell Characteristics of Human γδ T Lymphocytes in Chronic Myeloid Leukemia.
Sawaisorn P; Tangchaikeeree T; Chan-On W; Leepiyasakulchai C; Udomsangpetch R; Hongeng S; Jangpatarapongsa K
Immunol Invest; 2019 Jan; 48(1):11-26. PubMed ID: 30321079
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer.
Xu Y; Xiang Z; Alnaggar M; Kouakanou L; Li J; He J; Yang J; Hu Y; Chen Y; Lin L; Hao J; Li J; Chen J; Li M; Wu Q; Peters C; Zhou Q; Li J; Liang Y; Wang X; Han B; Ma M; Kabelitz D; Xu K; Tu W; Wu Y; Yin Z
Cell Mol Immunol; 2021 Feb; 18(2):427-439. PubMed ID: 32939032
[TBL] [Abstract][Full Text] [Related]
12. Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression.
Stolk D; van der Vliet HJ; de Gruijl TD; van Kooyk Y; Exley MA
Front Immunol; 2018; 9():1990. PubMed ID: 30298063
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting the Unconventionals: Importance of Immune Checkpoint Receptors in γδ T, MAIT, and NKT Cells.
Catafal-Tardos E; Baglioni MV; Bekiaris V
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572874
[TBL] [Abstract][Full Text] [Related]
14. CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells.
Dessarthe B; Thedrez A; Latouche JB; Cabillic F; Drouet A; Daniel P; de La Pintière CT; Catros V; Toutirais O
J Immunol; 2013 May; 190(9):4868-76. PubMed ID: 23530148
[TBL] [Abstract][Full Text] [Related]
15. The antitumor activity of human Vγ9Vδ2 T cells is impaired by TGF-β through significant phenotype, transcriptomic and metabolic changes.
Rafia C; Loizeau C; Renoult O; Harly C; Pecqueur C; Joalland N; Scotet E
Front Immunol; 2022; 13():1066336. PubMed ID: 36741364
[TBL] [Abstract][Full Text] [Related]
16. Metabolic approaches to rescue antitumor Vγ9Vδ2 T-cell functions in myeloma.
Castella B; Riganti C; Massaia M
Front Biosci (Landmark Ed); 2020 Jan; 25(1):69-105. PubMed ID: 31585878
[TBL] [Abstract][Full Text] [Related]
17. Human Vγ9Vδ2 T cells exert anti-tumor activity independently of PD-L1 expression in tumor cells.
Tomogane M; Sano Y; Shimizu D; Shimizu T; Miyashita M; Toda Y; Hosogi S; Tanaka Y; Kimura S; Ashihara E
Biochem Biophys Res Commun; 2021 Oct; 573():132-139. PubMed ID: 34407491
[TBL] [Abstract][Full Text] [Related]
18. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.
Braza MS; Klein B
Br J Haematol; 2013 Jan; 160(2):123-32. PubMed ID: 23061882
[TBL] [Abstract][Full Text] [Related]
20. Translating Unconventional T Cells and Their Roles in Leukemia Antitumor Immunity.
de Araújo ND; Gama FM; de Souza Barros M; Ribeiro TLP; Alves FS; Xabregas LA; Tarragô AM; Malheiro A; Costa AG
J Immunol Res; 2021; 2021():6633824. PubMed ID: 33506055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
